CE25-149 - Rigorous Evaluation of Community-Delivered Short- and Long-Acting Buprenorphine to People who Experience Homelessness or Live at Permanent Supportive Housing Sites
- Institution
- SEATTLE-KING COUNTY PUBLIC HEALTH DEPT, WA
- Principal investigator
- Julia Elizabeth Hood
- Funding
- $350K
- Duration
- 2025–2028
Moonbase score
Still being scored
Abstract
Project Abstract The intersection of the overdose and housing crises has prompted unprecedented mortality among our nation’s most vulnerable residents – people who experience homelessness (PEH). Multilevel barriers to care often obstruct this population’s access to medications for opioid use disorder (MOUD) -- a secondary overdose prevention strategy that halves the risk of overdose and improves other health outcomes. To eliminate the barriers associated with traveling to healthcare facilities for MOUD appointments and prescription refills, Public Health – Seattle and King County (PHSKC) will pilot a new MOUD service delivery model. Starting in 2025, buprenorphine prescriptions ordered during street medicine or telemedicine encounters at participating encampments, shelters and permanent supportive housing (PSH) sites will be filled at the Downtown Public Health Pharmacy and transported by a nurse-led care team, who will disburse short-acting sublingual and administer long-acting injectable buprenorphine directly to patients in the field. This study will employ a Type 2 Implementation-Effectiveness Hybrid design to evaluate this pilot program. Using quasi-experimental methods, we will evaluate the effect of community-delivered buprenorphine on (i) the risk of overdose in a propensity score matched patient cohort and (ii) occurrence of overdose at PSH sites, assessed via interrupted time series. Guided by the RE-AIM Implementation Science Framework, we will measure patient-level and systems-level implementation outcomes. This rigorous evaluation will generate real-world evidence for a (i) community-based MOUD delivery model and (ii) long-acting injectable buprenorphine. Findings from this evaluation will inform how these innovations can be adapted and brought to scale both locally and in other jurisdictions that grapple with the syndemic overdose and housing crises.
LOADING MOONBASE SCORE
Questions for Seattle-King County Public Health Dept
Seattle-King County Public Health Dept hasn't set up its Moonbase portfolio yet, so questions about this research can't be asked here.
Related grants
Same topic, scored first.
- NIH · New York University School of MedicineNot yet scored
Strengthening buprenorphine treatment for Individuals in carceral settings (STAND): A hybrid implementation-effectiveness trial of long-acting injectable versus sublingual buprenorphine
Jan Gryczynski · $1.4M · 2025–2030
- NIH · University of California Los AngelesNot yet scored
Adoption and scale-up of long-acting medications for opioid use disorder by U.S. clinicians.
Chelsea Leigh Shover · $179K · 2021–2026
- NIH · University of California, San DiegoNot yet scored
A Mixed-Methods Study of Novel Housing Programs and Overdose Outcomes Among Unhoused People Who Use Drugs in San Diego, California
Jesse Lloyd Goldshear · $200K · 2025–2030